'Clinically relevant' new drug interactions;'Klinisch bedeutsame' neue arzneimittelinteraktionen

Medizinische Klinik

Volumn 94, Issue 2, 1999, Pages 120-124

  Fuhr, Uwe ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Drug interactions; Grapefruit juice; HMG CoA reductase inhibitors; Mibefradil; Protease inhibitors; Selective serotonin re uptake inhibitors; Sildenafil

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIBEFRADIL; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL;

DRUG CHOICE; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; FOOD DRUG INTERACTION; FRUIT; REVIEW; DRUG COMBINATION; DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; HUMAN; RISK FACTOR;

CITRUS X PARADISI;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; RISK FACTORS;

EID: 0033556864     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044714     Document Type: Review

References (22)

1. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-77.
2. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmakokinetics, metabolism, and adverse reactions. Clin Ther 1998;20:2-25.
3. Bergendal L, Friberg A, Schaffrath AM. Potential drug -drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995;17:152-7.
4. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998;34:281-302.
5. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998;80:1-34.
6. de Mey C. Klinisch-pharmakologisches Profil: Sildenafilzitrat (Viagra). Klin Pharmakol Akt 1998;9:87-90.
7. Fuhr U. Drug interactions with grapefruit juice: Extent, probable mechanism, and clinical relevance. Drug Safety 1998;18:251-72.
8. Garg SK, Kumar N, Bhargava VK. et al. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther 1998;64:286-8.
9. Hansten PD, Horn JR. Hansten and Horn's drug interactions analysis and management (including update by Drug Interactions Newsletter up to April 1998). Vancouver: Applied Therapeutics Inc., 1997.
10. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Safety 1993;9:51-9
11. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402.
12. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review. J Clin Psychopharmacol 1997;17:208-21.
13. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998;279:1200-5.
14. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatm acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
15. McInnes GT, Brodie MJ. Drug interactions that matter. A critical reappraisal. Drugs 1988;36:83-110.
16. Nightingale SL. From the food and drug administration: Two new warnings added to the labeling for mibefradil. JAMA 1998;279:346.
17. Ozminkowski RJ, Hylan TR, Melfi CA, et al. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P450 system. Clin Ther 1998;20:780-96.
18. Pfizer Inc. Revised Viagra Label as of 11/24/1998. New York: Pfizer Labs, 1998.
19. Sproule BA, Naranjo CA, Brenmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
20. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
21. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
22. von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998;87:1184-9.